This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Psioxus Therapeutics Limited. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Matthieu Besneux: Innovator in Oncolytic Virus Research
Introduction
Matthieu Besneux is a notable inventor based in Oxfordshire, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development of oncolytic viruses.
Latest Patents
Besneux holds a patent for an oncolytic virus and method. This invention involves a replication competent virus that includes a transgene cassette encoding an anti-CD40 antibody or its binding fragment. The transgene cassette comprises an amino acid sequence specified in SEQ ID NO: 12 or a sequence that is at least 95% identical to it. The patent also covers pharmaceutical compositions that utilize this oncolytic virus, methods for preparing the virus and compositions, and their application in cancer treatment, particularly for patients with cancers that express CD40.
Career Highlights
Matthieu Besneux is associated with Psioxus Therapeutics Limited, where he continues to advance his research in oncolytic viruses. His work focuses on developing therapies that target specific cancer types, enhancing treatment efficacy for patients.
Collaborations
Besneux collaborates with esteemed colleagues, including Brian Robert Champion and Alice Claire Noel Bromley. Their combined expertise contributes to the innovative research environment at Psioxus Therapeutics Limited.
Conclusion
Matthieu Besneux's work in the field of oncolytic viruses represents a significant advancement in cancer therapy. His innovative approach and dedication to research continue to pave the way for new treatment options for patients.